Veracyte Inc(VCYT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:15 PM ET (Korea 9/12 05:15)
Full metrics table
| Index | RUT | P/E | 29 | EPS (ttm) | 1.41 | Insider Own | 1.91% | Shs Outstand | 80.4M | Perf Week | -8.51% |
| Market Cap | 3.29B | Forward P/E | 20.9 | EPS next Y | 2.14% | Insider Trans | -12.96% | Shs Float | 78.9M | Perf Month | -8.53% |
| Enterprise Value | 2.84B | PEG | 3.94 | EPS next Q | 0.41 | Inst Own | 110.99% | Short Float | 10.24% | Perf Quarter | -13.81% |
| Income | 0.11B | P/S | 5.85 | EPS this Y | 7.54% | Inst Trans | 0.83% | Short Ratio | 6.08 | Perf Half Y | 32.14% |
| Sales | 0.56B | P/B | 2.37 | EPS next 5Y | 5.3% | ROA | 8.09% | Short Interest | 8.08M | Perf YTD | -2.92% |
| Book/sh | 17.28 | P/C | 6.77 | EPS past 3/5Y | - | ROE | 8.77% | 52W High | -32.9% ($60.91) | Perf Year | 28.28% |
| Cash/sh | 6.04 | P/FCF | 19.79 | Sales past 3/5Y | 20.37% 34.5% | ROIC | 8.05% | 52W Low | 38.75% ($29.45) | Perf 3Y | 61.61% |
| Dividend Est. | - | EV/EBITDA | 24.15 | EPS Y/Y TTM | 323.64% | Gross Margin | 71.08% | Volatility(W/M) | 4.68% 4.47% | Perf 5Y | -16.01% |
| Dividend TTM | - | EV/Sales | 5.06 | Sales Y/Y TTM | 17.28% | Oper. Margin | 17.22% | ATR (14) | 2.12 | Perf 10Y | 522.07% |
| Dividend Ex-Date | - | Quick Ratio | 8.8 | EPS Q/Q | 2584.8% | Profit Margin | 20.37% | RSI (14) | 37.93 | Recom | 1.46 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.16 | Sales Q/Q | 15.49% | SMA20 | -4.58% ($42.83) | Beta | 1.96 | Target Price | $58.42 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/7/30 | SMA50 | -17.11% ($49.31) | Rel Volume | 0.75 | Prev Close | $42.03 |
| Employees | 755 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 31.61% 3.96% | SMA200 | -4.23% ($42.68) | Avg Volume(3M) | 1.33M | Price | $40.87 |
| IPO | 2013/10/30 | Option/Short | Yes/Yes | Trades | 12707 | Volume | 1,001,617 | Change | -2.76% |
Company
VCYT is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A diagnostic company providing genome-based cancer diagnostic testing. It offers genomic tests for cancer diagnosis and prognosis prediction, including thyroid, prostate, and lung cancers, and is growing through increased test volume and the launch of new tests. The company specializes in the genome-based cancer diagnostics field.
Over the past 1 year, roughly in the middle
33% below its 1-year high.
VCYT makes money exceptionally well
17.22% of revenue is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +7.5% this year.
Tap to view numbers
The price looks about right
Trading at 29.0 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +61.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 111.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
FBT 0.05%
GNOM 0.04%
ARKG 0.03%
PBE 0.03%
PSCH 0.02%It ranks #4 in the industry
Based on market cap of $3B.
VCYT $3B PER 29.0
TMO $225B PER 32.8
DHR $141B PER 35.5
NTRA $47B PER -
FAQ
What kind of company is VCYT?
VCYT belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of VCYT?
The market cap of VCYT is approximately $3.3B, ranking 1,720 within its sector.
What is the P/E ratio of VCYT?
VCYT has a P/E ratio of approximately 29.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for VCYT?
VCYT has recorded a 52-week high of $60.91 and a low of $29.45.
